Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/OCF
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Price to Operating Cash Flow (P/OCF) ratio compares a company`s market value to the cash it generates from its core operations.
Valuation Scenarios
If P/OCF returns to its 3-Year Average (42.9), the stock would be worth ₹992.95 (10% downside from current price).
| Scenario | P/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 47.6 | ₹1 102.15 |
0%
|
| 3-Year Average | 42.9 | ₹992.95 |
-10%
|
| 5-Year Average | 36.8 | ₹853.62 |
-23%
|
| Industry Average | 36.2 | ₹838.21 |
-24%
|
| Country Average | 23 | ₹531.86 |
-52%
|
Forward P/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | P/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| IN |
|
Vijaya Diagnostic Centre Ltd
NSE:VIJAYA
|
114.1B INR | 47.6 | 71 | |
| US |
|
CVS Health Corp
NYSE:CVS
|
106.6B USD | 10 | 60.3 | |
| US |
C
|
Cigna Group
XMUN:CGN
|
71B EUR | 8.5 | 13.7 | |
| US |
|
Cigna Corp
NYSE:CI
|
77B USD | 0 | 12.9 | |
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.3B EUR | 9.1 | 18.4 | |
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
22.5B EUR | 8.4 | 22.9 | |
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21B USD | 11.4 | 20.6 | |
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.1B USD | 12.9 | 24.1 | |
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
10.6B EUR | 4 | 10.9 | |
| US |
|
Guardant Health Inc
NASDAQ:GH
|
10.9B USD | -59 | -26.2 | |
| US |
|
DaVita Inc
NYSE:DVA
|
10.4B USD | 5.5 | 14 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 14 |
| Median | 23 |
| 70th Percentile | 39.7 |
| Max | 28 676 |
Other Multiples
Vijaya Diagnostic Centre Ltd
Glance View
In the bustling corridors of India's healthcare landscape, Vijaya Diagnostic Centre Ltd. stands as a beacon of precision and reliability. Founded in 1981 in Hyderabad, the company has grown from a single diagnostic center into a formidable network offering a wide array of testing services. With its roots firmly embedded in pathology and radiology, Vijaya combines state-of-the-art technology with a commitment to precision and accuracy, serving millions of patients across numerous locations. Every day, the company's centers buzz with activity as skilled technicians and medical professionals process a vast spectrum of tests and screenings, ranging from routine blood work to advanced imaging services. Vijaya Diagnostic Centre's business model is built upon delivering accurate diagnostic results efficiently, which forms the foundation of its revenue stream. As patients increasingly prioritize quality diagnostics for effective treatment, Vijaya ensures its services remain accessible across its widespread network. With the rising demand for healthcare services in India, paired with an increase in lifestyle-related ailments requiring regular monitoring, Vijaya positions itself strategically by continually expanding its reach and service offerings. Revenues pour in through direct patient payments and collaborations with medical institutions, cementing its role as a critical partner in preventive healthcare and diagnosis-driven wellness strategies.